Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.
Vivos Therapeutics, Inc. develops and commercializes medical technology and healthcare services for breathing-related sleep disorders, including obstructive sleep apnea and snoring associated with dentofacial abnormalities. Its Complete Airway Repositioning and Expansion (CARE) oral devices have FDA 510(k) clearances for adult OSA patients across severity levels and for moderate-to-severe OSA in children ages 6 to 17.
Company news commonly covers financial results, sleep testing services, treatment-center activity, and the integration of The Sleep Center of Nevada operating assets. Updates also address the shift toward a medical-affiliation distribution model, payer-network status for supported professional practices, collaborations for airway and sleep technologies, and capital actions such as warrant exercises and private placements.
Vivos Therapeutics (NASDAQ: VVOS), a medical device company specializing in sleep-related breathing disorders treatments, has announced a $4.3 million registered direct offering of common stock. The offering involves the sale of 1,363,812 shares at $3.15 per share, priced at-the-market under Nasdaq rules. No warrants are being issued. The offering is expected to close around September 20, 2024, with H.C. Wainwright & Co. acting as the exclusive placement agent. Vivos intends to use the net proceeds for working capital and general corporate purposes. The offering is made pursuant to a previously filed and effective shelf registration statement.
Vivos Therapeutics (NASDAQ: VVOS) has received a groundbreaking FDA 510(k) clearance for its DNA appliance to treat moderate to severe obstructive sleep apnea (OSA) and snoring in children aged 6 to 17. This is believed to be the first such clearance for an oral medical device in pediatric OSA treatment. The approval is based on a multi-site clinical trial that showed significant improvements in OSA symptoms and airway volumes.
Key findings from the study include:
- 50% reduction in sleep-related breathing disorder symptoms
- 58% decrease in snoring
- 62.7% improvement in moderate and severe AHI measurements
- 40% increase in airway volumes
Vivos aims to disrupt the pediatric OSA market, estimated at 10.1 million U.S. children, with its non-invasive, safe, and effective treatment option.
Vivos Therapeutics (NASDAQ: VVOS) reported strong Q2 2024 financial results, with revenue increasing 19% both sequentially and year-over-year to $4.1 million. The company saw operating expenses decrease by 31%, marking eight consecutive quarters of year-over-year improvement. Gross profit rose to $2.7 million, with gross margin increasing to 65%. Vivos' cost-cutting initiatives led to a significant 57% reduction in operating loss. The company anticipates achieving positive cash flow in early 2025.
Key developments include receiving regulatory approvals for Medicare reimbursement of CARE oral devices, a strategic marketing alliance with a Colorado sleep center operator, and a $7.5 million equity investment from New Seneca Partners. Vivos also reported positive results from a marketing pilot for its new distribution model, with 79% of newly diagnosed OSA patients choosing Vivos' oral appliance therapy.
Vivos Therapeutics (NASDAQ: VVOS), a leading medical device company focusing on sleep-related breathing disorders, has announced the release of its second quarter 2024 financial results after market close on August 14, 2024. The company will host a conference call at 5:00 pm ET on the same day to discuss the results and provide updates on recent achievements and developments.
Investors can access the call by dialing (800) 717-1738 (US) or (646) 307-1865 (international). A replay will be available until August 28, 2024, accessible by dialing (844) 512-2921 (US) or (412) 317-6671 (international) with passcode 1157721. A live webcast and 30-day archive will be available on the company's investor relations website.
Vivos Therapeutics announced positive results from a 7-month, multi-site pilot of its new provider-based marketing and distribution model. Conducted in seven dental and one ENT office, the pilot involved 99 patients with diverse demographics. 79% of newly diagnosed adult OSA patients preferred Vivos' oral appliance therapy over CPAP, with Vivos' devices chosen 5 to 1 over traditional appliances. Pediatric patients with orofacial issues were also successfully treated. Vivos aims to drive revenue through collaborations with dentists and sleep specialists, expecting positive impacts on new cases, revenue growth, and gross profit.
Vivos Therapeutics (NASDAQ: VVOS) announced a $7.5 million private equity investment from Seneca Partners to support a new strategic alliance with sleep treatment centers in Colorado. The alliance aims to enhance revenue through a new marketing and distribution model for Vivos' OSA treatment devices, starting with two centers in July 2024. Vivos intends to expand this model nationally. The investment boosts Vivos' cash reserves and shareholders' equity. Seneca will also offer management advisory services. Key investment terms include the purchase of 3,220,266 shares and associated warrants, with an 'at the market' price of $2.329 per share.
Vivos Therapeutics (NASDAQ: VVOS) reported Q1 2024 financial results, highlighting a 22% reduction in operating expenses and a gross margin of 57%. Revenue for Q1 2024 was $3.4 million, down from $3.8 million in Q1 2023, due to lower VIP enrollments and CARE appliance revenue. However, revenue from pediatric and lifeline appliances and home sleep testing services increased. Gross profit was $1.9 million. Despite revenue decline, cost-cutting initiatives reduced operating loss by 24% year-over-year. Cash and cash equivalents were $2.6 million. Over 42,600 patients have been treated with Vivos' devices, and regulatory approvals for Medicare reimbursement were obtained in April 2024. The company expects positive cash flow by end-2024, driven by new strategic revenue initiatives and improved market conditions.
Vivos Therapeutics (NASDAQ: VVOS), a key player in medical devices for sleep-related breathing disorders, will release its Q1 2024 financial results today, May 14, 2024, after market close. The company will hold a conference call at 5:00 p.m. ET to discuss financial results and recent milestones. Investors can join the call via provided phone numbers or access a live webcast on the company's website. A replay of the call will be available until May 28, 2024.
Summary not available.
Summary not available.